| Ying Zan,Xiaoyan Gao,Hongbing Ma,Liang Ling,Yuguang Ma,Wentao Hui. A retrospective clinical study of safety and efficacy of vinorelbine/epirubicin/fluorouracil (NEF) regimen as a postoperative chemotherapy for breast cancer. Oncol Transl Med, 2014, 13: 264-266. |
| A retrospective clinical study of safety and efficacy of vinorelbine/epirubicin/fluorouracil (NEF) regimen as a postoperative chemotherapy for breast cancer |
| |
| View Full Text View/Add Comment Download reader |
| KeyWord:vinorelbine/epirubicin/fluorouracil; breast cancer; adjuvant chemotherapy |
| Author Name | Affiliation | | Ying Zan | Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710004, China | | Xiaoyan Gao | Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710005, China | | Hongbing Ma | Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710006, China | | Liang Ling | Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710007, China | | Yuguang Ma | Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710008, China | | Wentao Hui | Department of Oncology, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Xi’an 710009, China |
|
| Hits: 7211 |
| Download times: 7481 |
| Abstract: |
| Objective: We aimed to investigate the safety and efficiency of vinorelbine/epirubicin/fluorouracil (NEF) regimen as adjuvant chemotherapy for breast cancer. Methods: From 2005 to 2008, 227 female breast cancer patients were treated with the NEF regimen: vinorelbine 25 mg/m2 iv on days 1 and 8; epirubicin 60 mg/m2 iv gtt on day 1; 5-Fu 500 mg/m2 iv gtt on day 1. Chemotherapy was repeated every 21–28 days for a total of 6 cycles. Results: The major side effects were neutropenia and gastrointestinal syndrome, with a 5-year survival rate of 85.4%. Conclusion: NEF regimen is safe and guarantees a high survival rate which could be recommended as a adjuvant chemotherapy regimen for breast cancer. |
| Close |
|
|
|